169 lines
52 KiB
Text
169 lines
52 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK24580">
|
|
<meta name="ncbi_domain" content="micad">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK24580/?report=reader">
|
|
<meta name="ncbi_pagename" content="99mTc-Labeled trans-1,2-cyclohexyldinitrilo tetramethylene phosphonic acid - Molecular Imaging and Contrast Agent Database (MICAD) - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>99mTc-Labeled trans-1,2-cyclohexyldinitrilo tetramethylene phosphonic acid - Molecular Imaging and Contrast Agent Database (MICAD) - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/micad/TEPAfolate99mTc/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/micad/TAGpepI99mTc/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/micad/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="Molecular Imaging and Contrast Agent Database (MICAD) [Internet]">
|
|
<meta name="citation_title" content="99mTc-Labeled trans-1,2-cyclohexyldinitrilo tetramethylene phosphonic acid">
|
|
<meta name="citation_publisher" content="National Center for Biotechnology Information (US)">
|
|
<meta name="citation_date" content="2009/10/15">
|
|
<meta name="citation_author" content="Puja Panwar">
|
|
<meta name="citation_author" content="Krishna Chuttani">
|
|
<meta name="citation_author" content="Pushpa Mishra">
|
|
<meta name="citation_author" content="Rajnish Sharma">
|
|
<meta name="citation_author" content="Anupam Mondal">
|
|
<meta name="citation_author" content="Anil Kumar Mishra">
|
|
<meta name="citation_author" content="Arvind Chopra">
|
|
<meta name="citation_pmid" content="20641928">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK24580/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="99mTc-Labeled trans-1,2-cyclohexyldinitrilo tetramethylene phosphonic acid">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Center for Biotechnology Information (US)">
|
|
<meta name="DC.Contributor" content="Puja Panwar">
|
|
<meta name="DC.Contributor" content="Krishna Chuttani">
|
|
<meta name="DC.Contributor" content="Pushpa Mishra">
|
|
<meta name="DC.Contributor" content="Rajnish Sharma">
|
|
<meta name="DC.Contributor" content="Anupam Mondal">
|
|
<meta name="DC.Contributor" content="Anil Kumar Mishra">
|
|
<meta name="DC.Contributor" content="Arvind Chopra">
|
|
<meta name="DC.Date" content="2009/10/15">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK24580/">
|
|
<meta name="description" content="Cancers such as those of the breast, prostate, kidney, and thyroid have a high incidence of metastases, particularly in the bone, which results in bone resorption, pain, hypercalcemia, spinal compression, decreased mobility, and even fractures (1). In addition, osteoporosis (bone resorption), a common condition experienced most frequently by menopausal women as well as aging women and men, often leads to bone fractures in these individuals (2). Although chemo- and radiotherapy are often used to treat bone metastases, none of these treatments control the progression of this disease or result in a better prognosis for the patient. Because of their attraction to hydroxyapatite, a major component of bone, bisphosponates (BPs) or their nitrogen-containing derivatives (N-BPs) are the most commonly used compounds for the selective targeting and treatment of bone-related ailments observed during cancer metastases or osteoporosis (3, 4). The chemical structure, characteristics, and pharmacological behavior of BPs and their derivatives have been described by Hirabayashi and Fujisaki (3). Briefly, the parent BP compound contains a characteristic phosphate-carbon-phosphate (P-C-P) bond that is resistant to enzymatic digestion and has no substitution at the central carbon (5); N-BPs, however, have a nitrogen-containing moiety substituted on the carbon atom (6). BPs and N-BPs have been shown to inhibit bone-related events by different mechanisms (7), and N-BPs were reported to be 100- to 10,000-fold more potent than BPs (8). Both BPs and N-BPs are approved by the United States Food and Drug Administration for the treatment of bone diseases such as osteoporosis, Paget’s disease of the bone, hypercalcemia, and bone metastases. In addition, these drugs are being evaluated in clinical trials for the treatment and imaging of different bone-related disorders.">
|
|
<meta name="og:title" content="99mTc-Labeled trans-1,2-cyclohexyldinitrilo tetramethylene phosphonic acid">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Cancers such as those of the breast, prostate, kidney, and thyroid have a high incidence of metastases, particularly in the bone, which results in bone resorption, pain, hypercalcemia, spinal compression, decreased mobility, and even fractures (1). In addition, osteoporosis (bone resorption), a common condition experienced most frequently by menopausal women as well as aging women and men, often leads to bone fractures in these individuals (2). Although chemo- and radiotherapy are often used to treat bone metastases, none of these treatments control the progression of this disease or result in a better prognosis for the patient. Because of their attraction to hydroxyapatite, a major component of bone, bisphosponates (BPs) or their nitrogen-containing derivatives (N-BPs) are the most commonly used compounds for the selective targeting and treatment of bone-related ailments observed during cancer metastases or osteoporosis (3, 4). The chemical structure, characteristics, and pharmacological behavior of BPs and their derivatives have been described by Hirabayashi and Fujisaki (3). Briefly, the parent BP compound contains a characteristic phosphate-carbon-phosphate (P-C-P) bond that is resistant to enzymatic digestion and has no substitution at the central carbon (5); N-BPs, however, have a nitrogen-containing moiety substituted on the carbon atom (6). BPs and N-BPs have been shown to inhibit bone-related events by different mechanisms (7), and N-BPs were reported to be 100- to 10,000-fold more potent than BPs (8). Both BPs and N-BPs are approved by the United States Food and Drug Administration for the treatment of bone diseases such as osteoporosis, Paget’s disease of the bone, hypercalcemia, and bone metastases. In addition, these drugs are being evaluated in clinical trials for the treatment and imaging of different bone-related disorders.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK24580/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-micad-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/micad/CDTMP99mTc/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK24580/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8B92A27D6415D10000000000AC0093.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK24580/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/micad/TEPAfolate99mTc/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">99mTc-Labeled trans-1,2-cyclohexyldinitrilo tetramethylene phosphonic acid</div><div class="j">Molecular Imaging and Contrast Agent Database (MICAD) [Internet]</div></div><div class="tail"><a href="/books/n/micad/TAGpepI99mTc/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK24580/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK24580/&text=99mTc-Labeled%20trans-1%2C2-cyclohexyldinitrilo%20tetramethylene%20phosphonic%20acid"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/micad/?report=reader">Title Information</a><a href="/books/n/micad/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK24580/?report=classic">Switch to classic view</a><a href="/books/NBK24580/pdf/Bookshelf_NBK24580.pdf">PDF (157K)</a><a href="/books/NBK24580/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK24580%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8B92A27D6415D10000000000AC0093.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK24580_"><span class="title" itemprop="name"><sup>99m</sup>Tc-Labeled <i>trans</i>-1,2-cyclohexyldinitrilo tetramethylene phosphonic acid</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm"> [<sup>99m</sup>Tc]CDTMP</div><p class="contribs">Panwar P, Chuttani K, Mishra P, et al.</p><p class="fm-aai"><a href="#_NBK24580_pubdet_">Publication Details</a></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figCDTMP99mTcTncchemicalname99mtclabele"><a href="/books/NBK24580/table/CDTMP99mTc.T.nc_chemical_name99mtclabele/?report=objectonly" target="object" title="Table" class="img_link icnblk_img" rid-ob="figobCDTMP99mTcTncchemicalname99mtclabele"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="CDTMP99mTc.T.nc_chemical_name99mtclabele"><a href="/books/NBK24580/table/CDTMP99mTc.T.nc_chemical_name99mtclabele/?report=objectonly" target="object" rid-ob="figobCDTMP99mTcTncchemicalname99mtclabele">Table</a></h4><p class="float-caption no_bottom_margin">
|
|
|
|
<i>In vitro</i>
|
|
|
|
|
|
Rodents
|
|
</p></div></div><div id="CDTMP99mTc.Background"><h2 id="_CDTMP99mTc_Background_">Background</h2><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=%22SUBSTANCENAME%22%5BSubstance%20Name%5D" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>Cancers such as those of the breast, prostate, kidney, and thyroid have a high incidence of metastases, particularly in the bone, which results in bone resorption, pain, hypercalcemia, spinal compression, decreased mobility, and even fractures (<a class="bibr" href="#CDTMP99mTc.REF.1" rid="CDTMP99mTc.REF.1">1</a>). In addition, osteoporosis (bone resorption), a common condition experienced most frequently by menopausal women as well as aging women and men, often leads to bone fractures in these individuals (<a class="bibr" href="#CDTMP99mTc.REF.2" rid="CDTMP99mTc.REF.2">2</a>). Although chemo- and radiotherapy are often used to treat bone metastases, none of these treatments control the progression of this disease or result in a better prognosis for the patient. Because of their attraction to hydroxyapatite, a major component of bone, bisphosponates (BPs) or their nitrogen-containing derivatives (N-BPs) are the most commonly used compounds for the selective targeting and treatment of bone-related ailments observed during cancer metastases or osteoporosis (<a class="bibr" href="#CDTMP99mTc.REF.3" rid="CDTMP99mTc.REF.3 CDTMP99mTc.REF.4">3, 4</a>). The chemical structure, characteristics, and pharmacological behavior of BPs and their derivatives have been described by Hirabayashi and Fujisaki (<a class="bibr" href="#CDTMP99mTc.REF.3" rid="CDTMP99mTc.REF.3">3</a>). Briefly, the parent BP compound contains a characteristic phosphate-carbon-phosphate (P-C-P) bond that is resistant to enzymatic digestion and has no substitution at the central carbon (<a class="bibr" href="#CDTMP99mTc.REF.5" rid="CDTMP99mTc.REF.5">5</a>); N-BPs, however, have a nitrogen-containing moiety substituted on the carbon atom (<a class="bibr" href="#CDTMP99mTc.REF.6" rid="CDTMP99mTc.REF.6">6</a>). BPs and N-BPs have been shown to inhibit bone-related events by different mechanisms (<a class="bibr" href="#CDTMP99mTc.REF.7" rid="CDTMP99mTc.REF.7">7</a>), and N-BPs were reported to be 100- to 10,000-fold more potent than BPs (<a class="bibr" href="#CDTMP99mTc.REF.8" rid="CDTMP99mTc.REF.8">8</a>). Both BPs and N-BPs are approved by the United States Food and Drug Administration for the treatment of bone diseases such as osteoporosis, Paget’s disease of the bone, hypercalcemia, and bone metastases. In addition, these drugs are being evaluated in <a href="http://clinicaltrials.gov/ct2/results?term=bisphosphonates" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">clinical trials</a> for the treatment and imaging of different bone-related disorders.</p><p>Accurate and early noninvasive detection of osteoporosis or bone metastases can assist in the development of a suitable treatment strategy and possibly improve the prognosis for a patient. Radiolabeled BPs, such as methyl diphosphonate (MDP) (<a class="bibr" href="#CDTMP99mTc.REF.9" rid="CDTMP99mTc.REF.9">9</a>), hydroxymethylene diphosphonate, 1-hydroxyethylene diphosphonate, etc., are often used as imaging agents for the detection of bone remodeling (e.g., during cancer metastases) or repair (e.g., after a fracture) because these compounds tend to accumulate in osteoclasts at active bone sites (<a class="bibr" href="#CDTMP99mTc.REF.10" rid="CDTMP99mTc.REF.10">10</a>). Although radiolabeled N-BPs have been used for the therapy of bone cancer in animals (<a class="bibr" href="#CDTMP99mTc.REF.11" rid="CDTMP99mTc.REF.11">11</a>) and humans (<a class="bibr" href="#CDTMP99mTc.REF.12" rid="CDTMP99mTc.REF.12">12</a>), no N-BPs have been evaluated or used for bone imaging. Panwar et al. (<a class="bibr" href="#CDTMP99mTc.REF.13" rid="CDTMP99mTc.REF.13">13</a>) synthesized a <sup>99m</sup>Tc-labeled multidentated N-BP, <i>trans</i>-1,2-cyclohexyldinitrilo tetramethylene phosphonic acid (<sup>99m</sup>Tc-CDTMP) and investigated its biodistribution in mice. The investigators also compared the whole-body scintigraphic images of rabbits treated with <sup>99m</sup>Tc-CDTMP with those obtained after treatment with <sup>99m</sup>Tc-MDP. In addition, imaging with <sup>99m</sup>Tc-CDTMP was performed on cancer patients with bone metastases, and the ratios of radioactivity accumulated in the bone lesion to soft tissue and the normal bone were determined.</p><div id="CDTMP99mTc.other"><h3>Other sources of information</h3><p><a href="/nuccore/NM_001037277.1" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Protein and mRNA sequence</a> of human farnesyl diphosphate synthase</p><p><a href="/gene/2224" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Gene information</a> regarding human farnesyl diphosphate synthase (GeneID: 2224)</p><p>Farnesyl diphosphate synthase in <a href="/omim/134629" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Online Mendelian Inheritance in Man (OMIM)</a></p><p><a href="/Structure/mmdb/mmdbsrv.cgi?uid=59201" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Structure of farnesyl diphosphate synthase</a> complexed with a bisphosphonate</p><p>Farnesyl diphosphate synthase in <a href="http://www.genome.jp/dbget-bin/www_bget?pathway+hsa00900" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathways</a></p><p><a href="/sites/entrez?db=Books&cmd=Search&term=Farnesyl+diphosphate+synthase++AND+micad%5Bbook%5D&doptcmdl=TOCView&log%24=booksrch&bname=micad" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Related chapters</a> in MICAD</p></div></div><div id="CDTMP99mTc.Synthesis"><h2 id="_CDTMP99mTc_Synthesis_">Synthesis</h2><p>[<a href="/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=99mTc-CDTMP+synthesis" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>The chemical synthesis of CDTMP was done as described by Panwar et al. (<a class="bibr" href="#CDTMP99mTc.REF.13" rid="CDTMP99mTc.REF.13">13</a>). The formation of CDTMP was confirmed with nuclear magnetic resonance spectroscopy, and the final yield of the compound was 92%.</p><p>The synthesis and specific activity of <sup>99m</sup>Tc-MDP used for some studies were not reported (<a class="bibr" href="#CDTMP99mTc.REF.13" rid="CDTMP99mTc.REF.13">13</a>).</p><p>The labeling of CDTMP with <sup>99m</sup>Tc was done in the presence of tin at a pH between 6.0 and 6.5 in 0.5 M sodium bicarbonate for 30 min at room temperature (<a class="bibr" href="#CDTMP99mTc.REF.13" rid="CDTMP99mTc.REF.13">13</a>). The yield of <sup>99m</sup>Tc-CDTMP was reported to be >97% with a radiochemical purity of >97% as determined with instant thin-layer paper chromatography–silica gel (ITLC-SC). The Rf of <sup>99m</sup>Tc-CDTMP on ITLC-SC was reported to be 0.3, which suggests that only one species of the labeled compound was formed during the labeling process. The specific activity of the radiochemical was not reported.</p></div><div id="CDTMP99mTc.In_Vitro_Studies_Testing_in_C"><h2 id="_CDTMP99mTc_In_Vitro_Studies_Testing_in_C_"><i>In Vitro</i> Studies: Testing in Cells and Tissues</h2><p>[<a href="/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=99mTc-CDTMP+in+vitro" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p><sup>99m</sup>Tc-CDTMP was reported to be stable in human serum for up to 24 h under <i>in vitro</i> physiological conditions (<a class="bibr" href="#CDTMP99mTc.REF.13" rid="CDTMP99mTc.REF.13">13</a>). Only 3% of the radioisotope was reported to be detached from the labeled compound during this period as determined with ITLC-SC.</p></div><div id="CDTMP99mTc.Animal_Studies"><h2 id="_CDTMP99mTc_Animal_Studies_">Animal Studies</h2><div id="CDTMP99mTc.Rodents"><h3>Rodents</h3><p>[<a href="/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=99mTc-CDTMP+rodentia" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>Panwar et al. investigated the biodistribution of <sup>99m</sup>Tc-CDTMP in BALB/c mice (<a class="bibr" href="#CDTMP99mTc.REF.13" rid="CDTMP99mTc.REF.13">13</a>). The animals (<i>n</i> = 5 mice/time point) were injected with the radiochemical through the tail vein and euthanized at predetermined intervals varying from 1 h to 24 h after treatment. Major organs of the animals were subsequently removed, and the incorporated radioactivity in each organ was determined (data were presented as percent injected dose/gram tissue ± standard deviation (% ID/g ± SD)). Maximum accumulation of <sup>99m</sup>Tc-CDTMP was observed in the bones of the animals (7.69 ± 0.65% ID/g at 1 h, 6.93 ± 0.36% ID/g at 4 h, and 6.22 ± 0.18% ID/g at 24 h), followed by the kidneys (1.04 ± 0.05% ID/g at 1 h, 1.52% ID/g at 4 h, and 0.28 ± 0.04% ID/g at 24 h). The uptake of radioactivity by the other organs varied from 0.09 ± 0.01% ID/g (heart) to 0.22 ± 0.01% ID/g (stomach) at 1 h, 0.05 ± 0.01% ID/g (intestines) to 0.16 ± 0.01% ID/g (lungs) at 4 h, and 0.02 ± 0.00% ID/g (blood) to 0.07 ± 0.01% ID/g (stomach and brain) at 24 h.</p><p>Although <sup>99m</sup>Tc-MDP was used for a study, the biodistribution of this radiotracer in mice was not reported (<a class="bibr" href="#CDTMP99mTc.REF.13" rid="CDTMP99mTc.REF.13">13</a>).</p><p>In another study, the bone/blood (B/B) and bone/muscle (B/M) uptake ratios of <sup>99m</sup>Tc-CDTMP and <sup>99m</sup>Tc-MDP were determined for the animals (<a class="bibr" href="#CDTMP99mTc.REF.13" rid="CDTMP99mTc.REF.13">13</a>). The B/B and B/M ratios for <sup>99m</sup>Tc-CDTMP were reported to be 40.4 and 54.9, respectively, and these ratios were higher than those for <sup>99m</sup>Tc-MDP (the actual B/B and B/M ratios for <sup>99m</sup>Tc-MDP were not reported).</p></div><div id="CDTMP99mTc.Other_NonPrimate_Mammals"><h3>Other Non-Primate Mammals</h3><p>[<a href="/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=99mTc-CDTMP+Non-Primate+Mammals" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>Scintigraphic studies were performed on rabbits injected with <sup>99m</sup>Tc-CDTMP (imaging was performed at 1 h after treatment); rabbits were also injected with <sup>99m</sup>Tc-MDP (imaging was performed at 3 h after treatment) for comparison purposes (<a class="bibr" href="#CDTMP99mTc.REF.13" rid="CDTMP99mTc.REF.13">13</a>). Compared with <sup>99m</sup>Tc-MDP, the bone uptake of <sup>99m</sup>Tc-CDTMP was rapid; however, a high accumulation of radioactivity in the kidneys of animals treated with <sup>99m</sup>Tc-CDTMP was evident. The investigators suggested that this was probably because the labeled aminophosphonate compound had a high affinity for the kidney tissue. This also showed that <sup>99m</sup>Tc-CDTMP was excreted primarily through the urinary route. No blocking studies with unlabeled CDTMP were reported sine the bone is considered a high capacity target site.</p></div><div id="CDTMP99mTc.NonHuman_Primates"><h3>Non-Human Primates</h3><p>[<a href="/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=99mTc-CDTMP+Non-Human+Primates" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>No references are currently available.</p></div></div><div id="CDTMP99mTc.Human_Studies"><h2 id="_CDTMP99mTc_Human_Studies_">Human Studies</h2><p>[<a href="/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=99mTc-CDTMP+Human+Studies" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>Eleven cancer patients with bone metastases were intravenously injected with <sup>99m</sup>Tc-CDTMP, and scintigraphy was performed on the individuals 1 h later as described by Panwar et al. (<a class="bibr" href="#CDTMP99mTc.REF.13" rid="CDTMP99mTc.REF.13">13</a>). Bone lesions were clearly visible in all the patients, and a semiquantitative region of interest analysis was performed to obtain the bone lesion/soft tissue (BL/ST) and bone lesion/normal bone (BL/NB) ratios. The BL/ST ratios for the patients varied from 5.6 ± 3.48 to 7.8 ± 1.10 with a mean of 6.8 ± 0.69. The BL/NB ratios varied from 5.36 ± 3.12 to 7.21 ± 0.68 with a mean of 5.67 ± 0.82.</p><p>From these studies the investigators concluded that <sup>99m</sup>Tc-CDTMP could be used to detect bone metastases in humans, and that CDTMP could perhaps be used to treat bone metastases after being labeled with a suitable high-energy nuclide (<a class="bibr" href="#CDTMP99mTc.REF.13" rid="CDTMP99mTc.REF.13">13</a>).</p></div><div id="CDTMP99mTc.Supplemental_Information"><h2 id="_CDTMP99mTc_Supplemental_Information_">Supplemental Information</h2><p>[<a href="/books/n/micad/disclaimer/?report=reader">Disclaimer</a>]</p><p>No information is currently available.</p></div><div id="CDTMP99mTc.References"><h2 id="_CDTMP99mTc_References_">References</h2><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="CDTMP99mTc.REF.1">Clark J.C., Dass C.R., Choong P.F.
|
|
<em>Current and future treatments of bone metastases.</em>
|
|
<span><span class="ref-journal">Expert Opin Emerg Drugs. </span>2008;<span class="ref-vol">13</span>(4):609–27.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19046130" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19046130</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="CDTMP99mTc.REF.2">Strewler G.J.
|
|
<em>Decimal point--osteoporosis therapy at the 10-year mark.</em>
|
|
<span><span class="ref-journal">N Engl J Med. </span>2004;<span class="ref-vol">350</span>(12):1172–4.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15028820" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15028820</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><div class="bk_ref" id="CDTMP99mTc.REF.3">Hirabayashi H., Fujisaki J.
|
|
<em>Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents.</em>
|
|
<span><span class="ref-journal">Clin Pharmacokinet. </span>2003;<span class="ref-vol">42</span>(15):1319–30.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14674786" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14674786</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd><div class="bk_ref" id="CDTMP99mTc.REF.4">Gittens S.A., Bansal G., Zernicke R.F., Uludag H.
|
|
<em>Designing proteins for bone targeting.</em>
|
|
<span><span class="ref-journal">Adv Drug Deliv Rev. </span>2005;<span class="ref-vol">57</span>(7):1011–36.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15876401" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15876401</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>5.</dt><dd><div class="bk_ref" id="CDTMP99mTc.REF.5">Cremers S.C., Pillai G., Papapoulos S.E.
|
|
<em>Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis.</em>
|
|
<span><span class="ref-journal">Clin Pharmacokinet. </span>2005;<span class="ref-vol">44</span>(6):551–70.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15932344" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15932344</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>6.</dt><dd><div class="bk_ref" id="CDTMP99mTc.REF.6">Stresing V., Daubine F., Benzaid I., Monkkonen H., Clezardin P.
|
|
<em>Bisphosphonates in cancer therapy.</em>
|
|
<span><span class="ref-journal">Cancer Lett. </span>2007;<span class="ref-vol">257</span>(1):16–35.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17697748" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17697748</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>7.</dt><dd><div class="bk_ref" id="CDTMP99mTc.REF.7">Winter M.C., Holen I., Coleman R.E.
|
|
<em>Exploring the anti-tumour activity of bisphosphonates in early breast cancer.</em>
|
|
<span><span class="ref-journal">Cancer Treat Rev. </span>2008;<span class="ref-vol">34</span>(5):453–75.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18423992" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18423992</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>8.</dt><dd><div class="bk_ref" id="CDTMP99mTc.REF.8">Kennel K.A., Drake M.T.
|
|
<em>Adverse effects of bisphosphonates: implications for osteoporosis management.</em>
|
|
<span><span class="ref-journal">Mayo Clin Proc. </span>2009;<span class="ref-vol">84</span>(7):632–7.</span> [<a href="/pmc/articles/PMC2704135/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2704135</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19567717" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19567717</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>9.</dt><dd><div class="bk_ref" id="CDTMP99mTc.REF.9">Chopra, A., <em>99mTc-Methyl diphosphonate.</em> Molecular Imaging and Contrast agent Database (MICAD) [database online]. National Library of Medicine, NCBI, Bethesda, MD, USA. Available from <a href="http://www.micad.nih.gov/" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">www<wbr style="display:inline-block"></wbr>​.micad.nih.gov</a>, 2004 -to current.</div></dd></dl><dl class="bkr_refwrap"><dt>10.</dt><dd><div class="bk_ref" id="CDTMP99mTc.REF.10">Arano Y.
|
|
<em>Recent advances in 99mTc radiopharmaceuticals.</em>
|
|
<span><span class="ref-journal">Ann Nucl Med. </span>2002;<span class="ref-vol">16</span>(2):79–93.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12043913" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12043913</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>11.</dt><dd><div class="bk_ref" id="CDTMP99mTc.REF.11">Essman S.C., Lewis M.R., Miller W.H.
|
|
<em>Intraorgan biodistribution and dosimetry of 153Sm-ethylenediaminetetramethylene phosphonate in juvenile rabbit tibia: implications for targeted radiotherapy of osteosarcoma.</em>
|
|
<span><span class="ref-journal">J Nucl Med. </span>2005;<span class="ref-vol">46</span>(12):2076–82.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16330573" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16330573</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>12.</dt><dd><div class="bk_ref" id="CDTMP99mTc.REF.12">Park I.H., Ro J., Nam B.H., Kwon Y., Lee K.S.
|
|
<em>Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases.</em>
|
|
<span><span class="ref-journal">BMC Cancer. </span>2009;<span class="ref-vol">9</span>:154.</span> [<a href="/pmc/articles/PMC2694816/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2694816</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19454038" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19454038</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>13.</dt><dd><div class="bk_ref" id="CDTMP99mTc.REF.13">Panwar P., Chuttani K., Mishra P., Sharma R., Mondal A., Kumar Mishra A.
|
|
<em>Synthesis of trans-1,2-cyclohexyldinitrilo tetramethylene phosphonic acid and its radiolabelling with 99mTc for the detection of skeletal metastases.</em>
|
|
<span><span class="ref-journal">Nucl Med Commun. </span>2006;<span class="ref-vol">27</span>(8):619–26.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16829762" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16829762</span></a>]</div></dd></dl></dl></div><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_top_margin"><div>This MICAD chapter is not included in the Open Access Subset, because it was authored / co-authored by one or more investigators who was not a member of the MICAD staff.</div></p></div></dd></dl></dl></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK24580_pubdet_">Publication Details</h2><h3>Author Information and Affiliations</h3><div class="contrib half_rhythm"><span itemprop="author">Puja Panwar</span>, PhD<div class="affiliation small">Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and allied Sciences, Delhi 110054, India<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ni.odrd.samni@ajup" class="oemail">ni.odrd.samni@ajup</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Krishna Chuttani</span>, MSc<div class="affiliation small">Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and allied Sciences, Delhi 110054, India<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="moc.oohay@inattuhck" class="oemail">moc.oohay@inattuhck</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Pushpa Mishra</span>, PhD<div class="affiliation small">Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and allied Sciences, Delhi 110054, India</div></div><div class="contrib half_rhythm"><span itemprop="author">Rajnish Sharma</span>, DRM, MNA, MS<div class="affiliation small">Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and allied Sciences, Delhi 110054, India</div></div><div class="contrib half_rhythm"><span itemprop="author">Anupam Mondal</span>, DRM, DNB<div class="affiliation small">Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and allied Sciences, Delhi 110054, India</div></div><div class="contrib half_rhythm"><span itemprop="author">Anil Kumar Mishra</span><div class="affiliation small">Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and allied Sciences, Delhi 110054, India<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.samni@arhsimka" class="oemail">gro.samni@arhsimka</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Arvind Chopra</span>, PhD<div class="affiliation small">National Center for Biotechnology Information, NLM, NIH, Bethesda, MD 20894<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.mln.ibcn@dacim" class="oemail">vog.hin.mln.ibcn@dacim</a></div></div></div><h3>Publication History</h3><p class="small">Created: <span itemprop="datePublished">August 19, 2009</span>; Last Update: <span itemprop="dateModified">October 15, 2009</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="http://www.ncbi.nlm.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Center for Biotechnology Information (US)</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>Panwar P, Chuttani K, Mishra P, et al. 99mTc-Labeled trans-1,2-cyclohexyldinitrilo tetramethylene phosphonic acid. 2009 Aug 19 [Updated 2009 Oct 15]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. <span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/micad/TEPAfolate99mTc/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/micad/TAGpepI99mTc/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobCDTMP99mTcTncchemicalname99mtclabele"><div id="CDTMP99mTc.T.nc_chemical_name99mtclabele" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK24580/table/CDTMP99mTc.T.nc_chemical_name99mtclabele/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__CDTMP99mTc.T.nc_chemical_name99mtclabele_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Chemical name:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><sup>99m</sup>Tc-Labeled <i>trans</i>-1,2-cyclohexyldinitrilo tetramethylene phosphonic acid<br /></td><td rowspan="9" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<span class="graphic"><img src="/books/NBK24580/bin/CDTMP99mTc.jpg" alt="Image CDTMP99mTc.jpg" /></span>
|
|
</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Abbreviated name:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">[<sup>99m</sup>Tc]CDTMP</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Synonym:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Agent Category:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Compound</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Target:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Farnesyl diphosphate synthase</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Target Category:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Enzyme</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Method of detection:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Single-photon emission computed tomography (SPECT); gamma planar imaging</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Source of signal / contrast:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><sup>99m</sup>Tc</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Activation:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Studies:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul class="simple-list"><li class="half_rhythm"><div>
|
|
<img alt="Checkbox" src="/corehtml/pmc/css/bookshelf/2.26/img/studies.checkbox.png" />
|
|
<i>In vitro</i>
|
|
|
|
</div></li><li class="half_rhythm"><div>
|
|
<img alt="Checkbox" src="/corehtml/pmc/css/bookshelf/2.26/img/studies.checkbox.png" /> Rodents
|
|
</div></li><li class="half_rhythm"><div>
|
|
<img alt="Checkbox" src="/corehtml/pmc/css/bookshelf/2.26/img/studies.checkbox.png" /> Non-primate non-rodent mammals
|
|
</div></li><li class="half_rhythm"><div>
|
|
<img alt="Checkbox" src="/corehtml/pmc/css/bookshelf/2.26/img/studies.checkbox.png" /> Humans
|
|
</div></li></ul>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Structure of CDTMP.</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal104 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|